News

AddToAny

Google+ Facebook Twitter Twitter

Test for Alzheimer’s 3.5 years before diagnosis

New research has established a blood-based test that could be used to predict the risk of Alzheimer’s disease up to 3.5 years before clinical diagnosis.

The study supports the idea that components in the human blood can modulate the formation of new brain cells, a process termed neurogenesis.

Neurogenesis occurs in an important part of the brain called the hippocampus that is involved in learning and memory.

While Alzheimer’s disease affects the formation of new brain cells in the hippocampus during the early stages of the disease, previous studies have only been able to study neurogenesis in its later stages through autopsies.

To understand the early changes, King’s College London researchers collected blood samples over several years from 56 individuals with mild cognitive impairment (MCI), a condition where someone will begin to experience a worsening of their memory or cognitive ability. 

Of the 56 participants in the study, 36 went on to receive a diagnosis of Alzheimer’s disease. Dr Aleksandra Maruszak, study joint first author, said: “We treated brain cells with blood taken from people with MCI, exploring how those cells changed in response to blood as Alzheimer’s disease progressed.”

In studying how blood affected the brain cells, the researchers made several key discoveries. The blood samples collected from participants over the years who subsequently deteriorated and developed Alzheimer’s disease promoted a decrease in cell growth and division and an increase in apoptotic cell death (the process by which cells are programmed to die). However, the researchers noted that these samples also increased the conversion of immature brain cells to hippocampal neurons.

bit.ly/3WQKiaV

Image credit | Science Photo Library

Related Articles

web_blood-testing_credit_istock-1384651794.png

SPONSORED: The power of automated gel-based ID-cards in routine immunohematology workflows

Immuno-haematology assays are pivotal to the carrying out of blood grouping, antibody screening and transfusions, and represent a critically time-dependent stage in the patient management pathway.

Technician holding a blood sample ready for testing with other human medical samples in the background.-Image credit - Science-Photo-Library-f0243823

Machine learning tool to detect cancer via liquid biopsy

US researchers have developed and tested an innovative machine-learning approach that could one day enable the earlier detection of cancer in patients by using smaller blood draws.

multiple myelomatosis-CREDIT-Science Photo Library-m132099

IBMS research grants

We look at the work of Dr Mosavar Farahani who received an IBMS Research Grant in 2023 to help fund her work on disease progression and skeletal complications in multiple myeloma.

Jaxon Moran and Emily Jones

My Lab: Flow cytometry laboratory

Jaxon Moran and Emily Jones give a guided tour of the Flow Cytometry Laboratory at Newcastle upon Tyne Hospitals NHS Foundation Trust.

Top